JNJ Approaches Record High, Analysts Warn of Valuation Risks

Johnson & Johnson (JNJ) is trading near its record high of $276.47, but analysts are recommending caution due to its high valuation.

The company has seen significant gains this year, with a 32% increase in value compared to the S&P 500's 12% gain. However, its trailing P/E ratio of 31 is considered elevated, and some analysts are warning that earnings disappointment could be a concern.

Despite these concerns, JNJ has several growth drivers, including oncology strength, immunology launches, and defensive rotation into large-cap pharma. The company's guidance for operational sales growth of 6.5% to 7.1% and adjusted operational EPS of $11.50 to $11.65 is also seen as a positive factor.

The FDA's approval of the Otava robotic surgical system is another catalyst for JNJ, providing a new growth engine for its MedTech segment. However, some analysts are cautioning that Stelara's decline may continue to pressure free cash flow towards its $21 billion target.